SERENEX TO BEGIN TRIAL OF SNX-1012 FOR CHEMOTHERAPY SIDE EFFECT

A A

Serenex announced the initiation of a Phase II clinical trial of its lead product, SNX-1012. The compound will be tested in patients with certain solid tumors who are treated with chemotherapy and develop oral mucositis. The study will compare multiple doses of SNX-1012 against a placebo control and is expected to be completed in early 2007.

SNX-1012 targets multiple inflammatory and other key pathways involved in the pathophysiology of oral mucositis. The product is administered as a topical, transmucosal agent in the form of an oral rinse that interferes with many of the biological targets necessary for mucositis development. Four Phase I trials have been successfully completed.